Reblozyl

Bristol Myers data make case for earlier use of bone marrow disease drug
Bristol Myers data make case for earlier use of bone marrow disease drug
BioPharma Dive
Bristol Myers Squibb
Reblozyl
Epogen
myelodysplastic syndromes
clinical trials
Flag link:
FDA Accepts sBLA of BMS' Reblozyl
FDA Accepts sBLA of BMS' Reblozyl
Targeted Oncology
Bristol Myers Squibb
Reblozyl
FDA
MDS
anemia
Flag link:
With positive trial results, Bristol Myers looks to widen use of blood disease drug
With positive trial results, Bristol Myers looks to widen use of blood disease drug
BioPharma Dive
Bristol Myers Squibb
Reblozyl
myelodysplastic syndrome
Flag link:
Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date
Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date
Endpoints
Bristol Myers Squibb
Reblozyl
beta thalassemia
Flag link:
Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod
Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod
Fierce Pharma
Bristol Myers Squibb
Merck
Reblozyl
FDA
beta thalassemia
Flag link:
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff
Fierce Pharma
JPMHC 2022
Bristol Myers Squibb
Revlimid
patent cliffs
Opdivo
Eliquis
Reblozyl
Breyanzi
Flag link:
Merck & Co justifies paying up for Acceleron
Merck & Co justifies paying up for Acceleron
EP Vantage
Merck
Accleron
M&A
sotatercept
Reblozyl
PAH
Flag link:
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Fierce Pharma
Bristol-Myers Squibb
generics
Revlimid
Zeposia
Reblozyl
Onureg
Flag link:
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches
Fierce Pharma
Celgene
Bristol-Myers Squibb
Zeposia
Reblozyl
Onureg
Flag link:
CHMP backs BMS’ first-in-class anemia drug Reblozyl
CHMP backs BMS’ first-in-class anemia drug Reblozyl
Pharmaforum
Bristol-Myers Squibb
EMA
CHMP
Reblozyl
anemia
Celgene
Flag link:
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Pharmaceutical Business Review
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
MDS
Flag link:
Go or no go? Covid-19 upstages US regulatory decisions
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Flag link:
A Big Month Ahead for the FDA and Bristol-Myers Squibb
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Flag link:
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
myelodysplastic syndromes
Flag link:
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
BioSpace
Celgene
Acceleron
Reblozyl
anemia
beta thalassemia
Flag link: